ENEST Clinical Trials Website - ENEST Logo
 
Search this website :
Home
For Healthcare Professionals Outside the U.S. Novartis Oncology Logo
Email Page – Evaluating Nilotinib Efficacy and Safety in Clinical Trials
Click here to email this page Click here to print this page


What is ENEST?
About Nilotinib
Disease Information
Tell a Colleague
Find Clinical Trial Information
About Novartis Oncology
Home Email Page
Email Page
After clicking the send button below, your friend will receive an e-mail from you containing an Internet link to this page.

All fields are required.
Your Name:
Your E-mail Address:
Friend's Email Address:
 
 
The e-mail addresses you furnish will be used solely to notify the recipient of the link to this page and that you have requested it be sent. The addresses will not be retained or reused.
Send   Reset
 
Disclaimer: This is intended for healthcare professionals. This is an international website for the ENEST (Evaluating Nilotinib Efficacy and Safety in Clinical Trials) program. The information on this site is not country-specific and may contain ENEST program information that is different from where you practice. Please contact your local Novartis representative for the latest ENEST information specific to your country.

The compound NILOTINIB described in this site has been approved in a number of countries for Ph+ CML; it has not been approved in any countries for KIT+ GIST. If NILOTINIB has not yet been approved in your country, there is no guarantee that NILOTINIB will become commercially available.
 
ENEST Home | What Is ENEST? | About NILOTINIB | Disease Information | Tell a Colleague About ENEST | Find Clinical Trial Information
About Novartis Oncology
© 2010 Novartis AG | Contact | Site Map | Privacy. Use of this Website is subject to our Terms of Use